share_log

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals' Da-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, And Lipid-Lowering Effects Compared to Survodutide, In Pre-Clinical Models

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals' Da-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, And Lipid-Lowering Effects Compared to Survodutide, In Pre-Clinical Models

NeuroBo Pharmaceuticals | 8-K:NeuroBo Pharmaceuticals的DA-1726在临床前模型中表现出比Survodutide更优的减肥、保持瘦体重和降脂效果
美股sec公告 ·  06/24 06:06
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息